title: The role of an all-oral chemotherapy containing lomustine (CCNU) in advanced,fs progressive Hodgkin lymphoma: a patient-friendly palliative option which can result in long-term disease control.
authors.affiliation: Northern Institute of Cancer Research, Academic Haematology, Medical School, Newcastle University. Electronic address: s.j.proctor@ncl.ac.uk.
authors.forename: S J
authors.initials: SJ
authors.lastname: Proctor
authors.affiliation: Department of Haematology.
authors.forename: A L
authors.initials: AL
authors.lastname: Lennard
authors.affiliation: Department of Haematology.
authors.forename: G H
authors.initials: GH
authors.lastname: Jackson
authors.affiliation: Department of Haematology.
authors.forename: G L
authors.initials: GL
authors.lastname: Jones
authors.affiliation: Northern Centre for Cancer Treatment, Newcastle NHS Hospital Foundation Trust.
authors.forename: J
authors.initials: J
authors.lastname: Lewis
authors.affiliation: Institute of Health and Society, Newcastle University.
authors.forename: J
authors.initials: J
authors.lastname: Wilkinson
authors.affiliation: Scotland and Newcastle Lymphoma Group, Academic Haematology, Medical School, Newcastle University, Newcastle upon Tyne.
authors.forename: J
authors.initials: J
authors.lastname: White
authors.affiliation: Northern Institute of Cancer Research, Academic Haematology, Medical School, Newcastle University.
authors.forename: M
authors.initials: M
authors.lastname: Sieniawski
authors.affiliation: Department of Haematology, Gartnavel General Hospital, Glasgow.
authors.forename: P
authors.initials: P
authors.lastname: McKay
authors.affiliation: Department of Haematology, Ward 16, Anchor Unit, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, UK.
authors.forename: D
authors.initials: D
authors.lastname: Culligan
authors.affiliation: Northern Centre for Cancer Treatment, Newcastle NHS Hospital Foundation Trust.
authors.forename: H H
authors.initials: HH
authors.lastname: Lucraft
mesh_terms: D000284:Administration, Oral; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002699:Chlorambucil / Q000008:administration & dosage / Q000009:adverse effects; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage* / Q000009:adverse effects; D010166:Palliative Care; D017060:Patient Satisfaction; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D016019:Survival Analysis; D017741:Survivors; D013997:Time Factors
chemical_list: D002699:Chlorambucil; D005047:Etoposide; D008130:Lomustine; D011239:Prednisolone